Shanghai Aladdin Biochemical Technology Co., Ltd (688179.SH) has signed a cooperation agreement with Feipeng Bioscience and plans to jointly establish a joint venture company.

Shanghai Aladdin Biochemical Technology Co., Ltd. (688179.SH) announced that the company signed a "Raw Material Reagent Incubation Project Transaction Framework Agreement" with Guangdong Feipeng Biotechnology Co., Ltd. (referred to as "Feipeng Biotechnology") on January 3, 2025. Through a series of transactions including the development of raw materials, reagents, and customized solutions, as well as asset, technology license, and service transfers, both parties intend to incubate the jointly established project company into a company with the capabilities of supplying raw materials, reagents, and solutions, as well as producing and independently researching raw materials and reagents. It is reported that Feipeng Biotechnology is a leading supplier of overall solutions for in vitro diagnostics and is a flagship enterprise in the industry. After nearly 20 years of technological accumulation and experience, Feipeng Biotechnology has gradually established a raw material product line covering mainstream platforms such as immunodiagnosis (enzyme-linked immunoassay, chemiluminescence, POCT, time-resolved fluorescence), clinical biochemistry (conventional biochemistry, latex turbidity), and molecular diagnostics (qPCR, isothermal amplification, high-throughput sequencing). It has broken the technical monopoly of foreign companies, and its raw material products can be widely used in areas such as in vitro diagnostics and scientific research testing.